Remdesivir
SARS-CoV-2 Infection
Professor Dr. Bernd MühlbauerSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the SARS-CoV-2 Infection cohort.
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →